Christi Freeman
Family · Bangor, MENPI 1205177383
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,490 and has fallen 99.0% since, to $15 in 2025. Among family clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$711
- Novo Nordisk$598
- Lilly USA, LLC$484
- Pfizer$197
- GSK$160
- Abbott$134
- plus $963 from 20 others
What the payments were for
- Food & beverage$3,238100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $711 |
| Novo Nordisk | 36 | $598 |
| Lilly USA, LLC | 26 | $484 |
| Pfizer | 11 | $197 |
| GSK | 9 | $160 |
| Abbott | 7 | $134 |
| Amgen | 7 | $109 |
| Astellas Pharma US Inc | 6 | $95 |
| Boehringer Ingelheim | 5 | $89 |
| Sumitomo Pharma America, Inc. | 6 | $87 |
| Xeris Pharmaceuticals, Inc. | 4 | $80 |
| Idorsia Pharmaceuticals US Inc | 4 | $74 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| Phathom Pharmaceuticals, Inc. | 3 | $60 |
| AstraZeneca | 4 | $58 |
| Johnson & Johnson | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Genentech USA, Inc. | 1 | $20 |
| Merck | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Lundbeck LLC | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,246 in reported general payments places this provider in the 95th percentile of 545 family providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 63 | $63,637 |
| JardianceEmpagliflozin | 63 | $57,890 |
| OzempicSemaglutide | 39 | $42,411 |
| JanuviaSitagliptin Phosphate | 30 | $32,943 |
| RexultiBrexpiprazole | 17 | $24,122 |
| MyrbetriqMirabegron | 24 | $18,117 |
| MounjaroTirzepatide | 16 | $16,588 |
| TradjentaLinagliptin | 24 | $11,463 |
| TrulicityDulaglutide | 11 | $10,279 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $9,993 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 12 | $2,510 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,404 |
| Memantine Hcl | 64 | $1,912 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 24 | $1,894 |
| Novolog FlexpenInsulin Aspart | 14 | $1,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $89 | $69,35387 claims |
| PfizerEliquis | $197 | $63,63763 claims |
| Novo NordiskOzempic | $598 | $42,41139 claims |
| MerckJanuvia | $18 | $32,94330 claims |
| Lilly USA, LLCMounjaro, Trulicity | $484 | $26,86727 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $24 | $24,12217 claims |
| Astellas Pharma US IncMyrbetriq | $95 | $18,11724 claims |
| AbbVieSynthroid | $711 | $91013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 545 family providers in Maine.
Other family in Bangor
- Jaclyn ForakerBangor$3K
- Giselle RobertsonBangor$2K
- Adrianne VelaBangor$2K
- Sheryl SparlinBangor$2K
- Amy SimBangor$2K
- Chelsea KamensBangor$2K
- Mia RapollaFalmouth$193K
- Patti DupreyKennebunk$35K
- Amanda WilliamsPortland$8K
- Jamie PiacentiniScarborough$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.